

**CCSS outcomes data is available to independent researchers through the CCSS review process.  
For additional information please contact the study at [ccss@stjude.org](mailto:ccss@stjude.org).**

## Summary Demographics Data

### Demographic and Cancer Characteristics of Eligible Study Subjects by Current Study Status

Characteristic		Eligible N (%)	Participant N (%)	No Baseline Data (Non-participant) N (%)	Lost To Follow-up N(%)	Pending N(%)
Total population		20276 (100%)	14054 (100%)	3132 (100%)	2996 (100%)	94 (100%)
Sex	Male	11208 ( 55%)	7541 ( 54%)	1939 ( 62%)	1675 ( 56%)	53 ( 56%)
	Female	9068 ( 45%)	6513 ( 46%)	1193 ( 38%)	1321 ( 44%)	41 ( 44%)
Race*	White	. .	11679 ( 87%)	. .	. .	. .
	Black	. .	291 ( 2%)	. .	. .	. .
	Hispanic	. .	635 ( 5%)	. .	. .	. .
	Asian/Pacific Islander	. .	165 ( 1%)	. .	. .	. .
	Other	. .	615 ( 5%)	. .	. .	. .
Diagnosis	ALL	5854 ( 29%)	4233 ( 29%)	783 ( 25%)	805 ( 27%)	33 ( 35%)
	AML	498 ( 2%)	357 ( 3%)	69 ( 2%)	69 ( 2%)	3 ( 3%)
	Other leukemia/NOS	313 ( 2%)	137 ( 2%)	104 ( 3%)	70 ( 2%)	2 ( 2%)
	Astrocytomas	1819 ( 9%)	1158 ( 8%)	337 ( 11%)	320 ( 11%)	4 ( 4%)
	Medullo/PNET	549 ( 3%)	366 ( 3%)	86 ( 3%)	92 ( 3%)	5 ( 5%)
	Other CNS tumors	468 ( 2%)	305 ( 2%)	83 ( 3%)	78 ( 3%)	2 ( 2%)
	Hodgkin's disease	2718 ( 13%)	1906 ( 14%)	431 ( 14%)	375 ( 13%)	6 ( 6%)
	Non-Hodgkin's lymph.	1488 ( 7%)	1054 ( 7%)	215 ( 7%)	208 ( 7%)	11 ( 12%)
	Kidney tumors	1684 ( 8%)	1214 ( 9%)	198 ( 6%)	264 ( 9%)	8 ( 9%)
	Neuroblastoma	1338 ( 7%)	928 ( 7%)	183 ( 6%)	221 ( 7%)	6 ( 6%)
	Soft tissue sarcoma	1815 ( 9%)	1222 ( 9%)	311 ( 10%)	276 ( 9%)	6 ( 6%)
	Ewing's sarcoma	561 ( 3%)	393 ( 3%)	109 ( 3%)	55 ( 2%)	4 ( 4%)
	Osteosarcoma	1071 ( 5%)	727 ( 5%)	192 ( 6%)	148 ( 5%)	4 ( 4%)
	Other bone tumors	99 (<1%)	53 (<1%)	31 ( 1%)	15 ( 1%)	0 .
Age at diagnosis	<1	1397 ( 7%)	975 ( 7%)	168 ( 5%)	247 ( 8%)	7 ( 7%)
	1-3	5089 ( 25%)	3539 ( 25%)	731 ( 23%)	775 ( 26%)	44 ( 47%)
	4-7	4553 ( 22%)	3157 ( 22%)	697 ( 22%)	678 ( 23%)	21 ( 22%)
	8-10	2290 ( 11%)	1538 ( 11%)	364 ( 12%)	383 ( 13%)	5 ( 5%)
	11-14	3396 ( 17%)	2373 ( 17%)	559 ( 18%)	458 ( 15%)	6 ( 6%)
	15-20	3551 ( 18%)	2472 ( 18%)	613 ( 20%)	455 ( 15%)	11 ( 12%)
Status at 12/31/96	Alive	18136 ( 90%)	12832 ( 91%)	2721 ( 87%)	2504 ( 84%)	79 ( 84%)
	Dead	2126 ( 10%)	1222 ( 9%)	411 ( 13%)	478 ( 16%)	15 ( 16%)
Age at 12/31/96	<20	6381 ( 32%)	4540 ( 32%)	833 ( 27%)	947 ( 32%)	61 ( 66%)
	20-29	8781 ( 44%)	5946 ( 42%)	1483 ( 48%)	1328 ( 45%)	24 ( 26%)
	30-39	4467 ( 22%)	3146 ( 22%)	703 ( 23%)	613 ( 21%)	5 ( 5%)
	40+	552 ( 3%)	385 ( 3%)	95 ( 3%)	70 ( 2%)	2 ( 2%)
Treatment modality	Surgery only (S)	1206 ( 8%)	901 ( 7%)	197 ( 14%)	108 ( 10%)	0 .
	Chemotherapy only (C)	918 ( 6%)	797 ( 6%)	73 ( 5%)	48 ( 4%)	0 .
	Radiation only (R)	48 (<1%)	32 (<1%)	13 ( 1%)	3 (<1%)	0 .
	C + R	1705 ( 11%)	1443 ( 12%)	137 ( 9%)	125 ( 12%)	0 .
	C + S	2634 ( 18%)	2237 ( 18%)	240 ( 17%)	154 ( 14%)	3 ( 30%)
	R + S	1881 ( 13%)	1477 ( 12%)	233 ( 16%)	168 ( 16%)	3 ( 30%)
	C + R + S	6516 ( 44%)	5491 ( 44%)	558 ( 38%)	463 ( 43%)	4 ( 40%)

\* Information regarding race is only available for participants. A more detailed categorization of race/ethnicity can be viewed at